Overview

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Status:
Completed

Trial end date:
2014-10-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether an optimal dose of [6R] 5,10-methylenetetrahydrofolate (arfolitixorin) in combination with pemetrexed are effective in pre-operative treatment of patients with resectable rectal cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Isofol Medical AB

Treatments:

Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Pemetrexed
Tetrahydrofolates